康方生物(09926.HK):PFS HR 0.51, mPFS 11.14個月依沃西單藥對比帕博利珠1L治療PD-L1表達陽性NSCLC(AK112-303/HARMONI-2)III期數據重磅發表於2024 WCLC
格隆匯9月9日丨康方生物(09926.HK)發佈公吿,AK112–303/HARMONi-2(CTR20222137)數據已在國際肺癌研究協會 (IASLC)主辦的2024年世界肺癌大會(WCLC)的全體會議主席專題研討會(Presidential Symposium)上發佈。該臨牀結果由主要研究者原上海市肺科醫院腫瘤科主任、現任同濟大學附屬東方醫院腫瘤科主任、IASLC候任主席周彩存教授以口頭報吿形式發表。
AK112-303/HARMONi-2(CTR20222137)是一項在中國開展的評估依達方®(依沃西,PD-1/VEGF)單藥與帕博利珠單藥對比一線治療PD-L1表達陽性(PD-L1 TPS≥1%)的局部晚期或轉移性NSCLC的註冊性III期隨機、雙盲臨牀試驗,主要研究終點為由IRRC據RECIST v1.1評估PFS,次要終點為OS、ORR、Do R和安全性等,共入組398例受試者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.